Multiple sclerosis (MS), a leading cause of non-traumatic disability in young adults,
is a chronic inflammatory demyelinating disease of the central nervous system (CNS)
associated with aberrant autoimmune responses. It has long been thought that therapeutic
development should be centered on immunomodulatory agents. However, none of the agents
tested could prevent chronic progressive disease and disability. On the other hand,
direct repair of injured myelin might represent an alternative strategy for treating
MS. This may be achieved by either promoting the inherent repair mechanism of neurons
or by recruiting cells derived from oligodendrocyte progenitor cells (OPCs), which
are unfortunately silent in MS. The latter approach was recently demonstrated by Najm
et al at Case Western Reserve University and Northwestern University.
1
They demonstrated that miconazole and clobetasol, screened from a library of bioactive
small molecules on mouse pluripotent epiblast stem cell-derived OPCs,2, 3, 4 promoted
precocious myelination, significantly increased the number of new oligodendrocytes
and enhanced remyelination. Strikingly, both small molecules reversed the disease
severity in mouse models of MS.
The subsequent genome-wide RNA sequencing and phosphoproteomic analyses on mouse OPCs
showed that the activity of clobetasol is mediated by the glucocorticoid receptor
signaling axis, whereas miconazole functions through the mitogen-activated protein
(MAP) kinase pathway, with potential cell-type specificity. To interpret the potential
impact of these treatments on immune cell survival and function, subsequent immune
response assays were performed, which showed that only clobetasol alters the naïve
T-cell differentiation and secretion of cytokines. These findings indicate that clobetasol
plays a role in both immunomodulation and the promotion of myelination, whereas miconazole
acts as a direct remyelinating agent, with no effect on the immune system. Most importantly,
both drugs enhanced the generation of human oligodendrocytes from human OPCs in vitro,
with miconazole exhibiting the most reproducible and potent effects. Although miconazole
and clobetasol are currently only approved for topical administration in humans, meaning
that significant optimization of the dosing, delivery and potentially the chemical
constitution will be required to enhance the on-target pharmacology in OPCs, this
study provides new hope for the currently untreatable chronic progressive phase of
MS.
It remains unknown how the remyelinating and immune system effects interact, and the
precise mechanisms underlying the resultant recovery after the administration of these
two drugs remain unclear. However, the study by Najm et al suggests that OPCs can
be selectively modified and differentiated into oligodendrocytes by two different
drugs identified using a high-throughput screening method, both of which resulted
in amelioration of the MS phenotype in vivo. Compared with genetically engineered
stem cells, which may exhibit alterations of their structure and function that might
interfere with the microenvironment and glia-neuron interactions, a major advantage
of using drug-modified cells is that the treatment can be stopped at any time depending
on the clinical outcome of the MS and the side effects. In addition, the manipulation
of isolated target cells provides a new method for dealing not only with MS, but also
with a variety of other diseases, such as cancer and neurodegenerative diseases. For
instance, the drug-based high-throughput screening strategy used in this study could
be useful to identify small molecules targeting cancer stem cells, which would ultimately
lead to the optimized treatment of patients with cancer. Therefore, we think that
the drug-based modulation of target cells represents a breakthrough in research related
to physiology and disease.